Statistical evidence from meta-analysis of VIVIAD and VIVA-MIND enables efficient design of Phase 2b study in diabetic kidney disease (DKD), ideally suited to evaluate varoglutamstat in the intended ...

Fibrate therapy may lower the risks of mortality and progression to end-stage kidney disease (ESKD), despite raising the risk for new onset stage 3 or higher chronic kidney disease (CKD), a new study ...

Immune checkpoint inhibitor-based combinations have become the preferred first-line therapy for patients with metastatic clear cell renal cell carcinoma, but more than a third of eligible patients do ...